FLT3 (ITD)

FLT3 · Variant type: indel · HGVS: p.internal tandem duplication aa591-601

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	99.9%	0.1%	78.23
2	Pralsetinib	99.3%	0.7%	93.43
3	Brigatinib	99.1%	0.9%	82.96
4	Sunitinib	98.3%	1.7%	91.73
5	Quizartinib	98.3%	1.7%	99.50
6	Nintedanib	98.1%	1.9%	90.23
7	Gilteritinib	98.1%	1.9%	88.97
8	Fostamatinib	98.0%	2.0%	96.74
9	Entrectinib	97.8%	2.2%	93.69
10	Pacritinib	97.4%	2.6%	88.64
11	Defactinib	97.3%	2.7%	92.68
12	Fedratinib	96.4%	3.6%	96.21
13	Cabozantinib	95.0%	5.0%	92.73
14	Sorafenib	94.6%	5.4%	96.72
15	Selpercatinib	94.4%	5.6%	96.72
16	Alectinib	93.5%	6.5%	95.49
17	Canertinib	92.0%	8.0%	96.49
18	Avapritinib	89.9%	10.1%	97.73
19	Erlotinib	83.8%	16.2%	99.75
20	Rabusertib	81.7%	18.3%	98.74
21	Tenalisib	80.3%	19.7%	97.98
22	Pexidartinib	79.7%	20.3%	99.49
23	Vandetanib	79.6%	20.4%	95.74
24	Alpelisib	78.2%	21.8%	97.22
25	Ripretinib	77.1%	22.9%	92.95

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	99.9%	97.9%	+2.0%
Pralsetinib	99.3%	97.6%	+1.7%
Brigatinib	99.1%	98.1%	+1.1%
Sunitinib	98.3%	98.7%	-0.4%
Quizartinib	98.3%	97.9%	+0.4%
Nintedanib	98.1%	95.2%	+2.9%
Gilteritinib	98.1%	99.2%	-1.1%
Fostamatinib	98.0%	97.2%	+0.8%
Entrectinib	97.8%	96.1%	+1.7%
Pacritinib	97.4%	93.6%	+3.8%
Defactinib	97.3%	94.6%	+2.7%
Fedratinib	96.4%	98.2%	-1.8%
Cabozantinib	95.0%	95.0%	+0.0%
Sorafenib	94.6%	97.3%	-2.7%
Selpercatinib	94.4%	96.1%	-1.8%
Alectinib	93.5%	84.5%	+9.0%
Canertinib	92.0%	86.3%	+5.7%
Avapritinib	89.9%	88.6%	+1.3%
Erlotinib	83.8%	—	—
Rabusertib	81.7%	—	—
Tenalisib	80.3%	—	—
Pexidartinib	79.7%	—	—
Vandetanib	79.6%	—	—
Alpelisib	78.2%	—	—
Ripretinib	77.1%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.9ms